Since the start of 2020, Moderna (NASDAQ: MRNA) stock is up an astounding 438%. In the announcement, management celebrated the successful conclusion of the phase 3 trials of the company's flu vaccine. It also noted that it would soon submit the data for its respiratory syncytial virus (RSV) drug to regulators for their evaluation too.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles